Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly But the Right Test Will Hear It
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“Not every antigen speaks loudly…
But the right test will hear it.
In transfusion medicine, one of the most fascinating diagnostic tools we use to unmask hidden ABO subgroups is the Adsorption and Elution Test.
When routine serology says:
‘No antigen detected…’
This test asks again:
‘Are you absolutely sure?’
And sometimes — it finds what others miss.
Why Adsorption and Elution Matters
Some ABO subgroups (like weak A, weak B, A₃, Aₓ) express very low antigen levels on red cells.
These antigens:
- may not react in routine forward grouping
- may remain undetected even after incubation
- can create ABO discrepancies
- can affect transfusion safety if overlooked
That’s where Adsorption and Elution testing becomes powerful.
It helps us detect the hidden antigen behind the silence.
The Principle (Simple but Powerful)
- Red cells are incubated with anti-A or anti-B antibodies
- Weak antigens adsorb (bind) those antibodies
- Bound antibodies are eluted (released) from the cells
- The eluate is tested with A or B pooled cells
- Agglutination confirms the presence of the weak antigen
This confirms what routine testing could not reveal.
When Should You Think About Using It?
Consider Adsorption and Elution testing when:
- Forward and reverse grouping don’t match
- Weak A or weak B subgroup suspected
- Investigating ABO discrepancies
- Testing neonates or immunocompromised patients
- Resolving uncertain pre-transfusion typing
Why This Test Is So Important
Because accurate ABO subgroup identification means:
- safer transfusion decisions
- fewer compatibility surprises
- stronger laboratory confidence
- better patient outcomes
In transfusion medicine, precision saves lives.
Not every antigen shouts.
But with the right technique, we can still hear its voice.
Do you routinely perform Adsorption and Elution testing in your blood bank when resolving subgroup discrepancies?
Let’s learn from each other — Blood Doki”
Other posts featuring Augustina Isioma Ikusemoro on Hemostasis Today.
-
Apr 22, 2026, 14:47Karuna Kumar: Busting the Myth about Increasing Infection Risk by IV Iron
-
Apr 22, 2026, 14:46David Brown: Charting a New Path Forward for One Patient Facing Extraordinary Cardiac Challenges
-
Apr 22, 2026, 14:45Ney Carter Borges: Syphilis and Cardiovascular Risk – A Silent and Progressive Vascular Burden
-
Apr 22, 2026, 14:44Sanjay Ahuja – New CEO and Medical Director of Innovative Hematology
-
Apr 22, 2026, 14:36Shivanand Kumatagi: Building Clinical Research Skills at the ASH CRTI Asia Pacific Program
-
Apr 22, 2026, 14:22Pradeep Natarajan: Can Polygenic Risk Scores Refine Risk Stratification in Secondary Prevention of CAD
-
Apr 22, 2026, 14:16Omar Adwan: Rare Genetic Disorders of Red Blood Cell Membrane Abnormalities
-
Apr 22, 2026, 14:10Alan Nurden: Pregnancy Challenges and Bleeding Risks in Inherited Platelet Disorders
-
Apr 22, 2026, 12:57Ali AlBahar: DNA Drives the Molecular Era of Blood Typing